BioNTech has created a breakthrough mRNA vaccine against devastating disease The German company, together with Pfizer, has created an innovative vaccine against CoVID-19, and has now developed a completely new drug for a completely different disease that affects millions of people around the world.

Many eminent scientists believe that the key to developing new specifics for the world's most dangerous diseases is mRNA technology, i.e. template RNA. After the vaccine / drug has been applied, it allows human cells to be printed with specific code that reprograms them so that they perform specific functions exactly as we want them to.

In other words, ordinary vaccines or drugs only tell the body's immune system to be careful about certain proteins, because they can pose a threat to it. However, the immune system decides for itself whether and what action to take in the event of a threat. Unfortunately, there may be no reaction whatsoever, which is why conventional vaccines are so ineffective.

It is completely different in the case of mRNA vaccines, such as the former for CoVID-19. Through the vaccine, the immune system is not informed about the threat, but is forced by the RNA to perform certain actions and perform it in a planned manner by the vaccine manufacturers, which is why these drugs are so effective.

Scientists inform that thanks to mRNA vaccines, our bodies can produce drugs for themselves and thus heal themselves of virtually any disease. It is a technology of the future that is currently under advanced development. The first demonstration of its effectiveness are the CoVID-19 vaccines from BioNTech, Pfizer or Moderna, which are based on mRNA.

BioNTech wants to use mRNA technology to create universal cancer drugs and vaccines, e.g. for influenza, which will work 10 years ahead. Here, supercomputers and artificial intelligence will be very helpful, with the help of which it will be possible to simulate and encode information in mRNA to fight against future mutations secret sites the virus.

Another success of BioNTech is the development of a new vaccine for multiple sclerosis. Nearly 3 million people worldwide suffer from it. In all people, the immune system attacks its own cells. Scientists have developed a technology for the application of specific proteins, thanks to which it is possible to seriously reduce the body's autoimmune effects and improve the quality of life of patients.

The first vaccine experiments in mice showed that the drug controls antigens to such an extent that in rodents, the disease-related neurological symptoms that degraded the body began to regress. Scientists believe that the launch of an effective drug for multiple sclerosis may take place in the next 2 years, and for most of the world's most dangerous diseases by 2040.